Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Taysha Gene Therapies Inc
(NQ:
TSHA
)
2.070
-0.080 (-3.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Taysha Gene Therapies Inc
< Previous
1
2
Next >
Taysha Gene Therapies Receives Orphan Drug Designation for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency From the European Commission
August 25, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease
August 17, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 16, 2021
From
Taysha Gene Therapies
Via
Business Wire
Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing
August 16, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 16
August 09, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Participate in Upcoming August Investor Healthcare Conferences
August 02, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Host Manufacturing Day
July 20, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Participate in Upcoming July Investor Healthcare Conference
July 08, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Announces Publication of Natural History Data for TSHA-120 in Giant Axonal Neuropathy in the Journal, Brain
June 21, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Host Virtual R&D Day
June 17, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum
June 15, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Host First Annual Stockholder Meeting
June 10, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Participate in Upcoming June Investor Healthcare Conferences
May 26, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Joins the Rare Disease Company Coalition
May 19, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Expands Leadership Team with the Appointment of Chief Development Officer
May 13, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Participate in Upcoming May Investor Healthcare Conferences
May 12, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update
May 11, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Announces Publication of Preclinical Data for TSHA-102 in Rett Syndrome in Brain, a Highly Esteemed Neurological Science Peer-Reviewed Journal
May 10, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
May 05, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11
May 04, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Announces New Data on Multiple Preclinical Programs and Upcoming R&D Day
April 14, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease
April 12, 2021
From
Taysha Gene Therapies, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.